| Autor: |
Ajibola Adeyemo, Aderonke, Shettar, Abhijith, Bhat, Imtiyaz Ahmad, Kondaiah, Paturu, Mukherjee, Partha Sarathi |
| Zdroj: |
Inorganic Chemistry; January 2017, Vol. 56 Issue: 1 p608-617, 10p |
| Abstrakt: |
Four new octanuclear Ru(II) cages (OC-1–OC-4) were synthesized from dinuclear p-cymene ruthenium(II) acceptors [Ru2(μ–η4-C2O4)(CH3OH)2(η6-p-cymene)2](O3SCF3)2(A1), [Ru2(μ–η4-C6H2O4)(CH3OH)2(η6-p-cymene)2](O3SCF3)2(A2), [Ru2(dhnq)(H2O)2(η6-p-cymene)2](O3SCF3)2(A3), and [Ru2(dhtq)(H2O)2(η6-p-cymene)2](O3SCF3)2(A4) separately with a tetradentate pyridyl ligand (L1) in methanol using coordination-driven self-assembly [L1= N,N,N′,N′-tetra(pyridin-4-yl)benzene-1,4-diamine]. The octanuclear cages are fully characterized by various spectroscopic techniques including single-crystal X-ray diffraction analysis of OC-4. The self-assembled cages show strong in vitro anticancer activity against human lung adenocarcinoma A549 and human cervical cancer HeLa cell lines as observed from the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Of all the octanuclear cages, OC-3exhibits remarkable anticancer activity against both cancer cell lines and is more active than that reported for cisplatin. The excellent anticancer activity of OC-3and OC-4highlights the importance of the synergistic effects of the spacer component of the dinuclear p-cymene Ru(II) acceptor clips. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
